New hope for rare pancreatic cancer patients after first treatment fails
NCT ID NCT07121478
Summary
This study is testing whether the drug lurbinectedin can help control high-grade pancreatic neuroendocrine tumors when standard treatments have stopped working. The trial will enroll 46 patients who have already tried other cancer therapies. Researchers will measure how well the drug shrinks tumors and how long patients live without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMOR OF PANCREAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center
Goyang-si, Gyeonggi-do, 10408, South Korea
Conditions
Explore the condition pages connected to this study.